{"groups":[{"description":"Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m\\^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.","id":"FG000","title":"Pertuzumab + Trastuzumab + Docetaxel"},{"description":"Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m\\^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.","id":"FG001","title":"Placebo + Trastuzumab + Docetaxel"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"235"},{"groupId":"FG001","numSubjects":"280"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"53"}],"type":"Withdrew Consent or Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"402"},{"groupId":"FG001","numSubjects":"406"}],"comment":"Intent-to-Treat (ITT) Population","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"Did Not Receive Any Study Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"399"},{"comment":"9 participants randomized to the Placebo arm actually received at least one dose of pertuzumab.","groupId":"FG001","numSubjects":"9"}],"comment":"Safety Population (Pertuzumab)","type":"Received at Least One Dose of Pertuzumab"},{"achievements":[{"comment":"1 participant randomized to the Pertuzumab arm actually received placebo at every treatment cycle.","groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"395"}],"comment":"Safety Population (Placebo)","type":"Received at Least One Dose of Placebo"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"comment":"From July 2012, 50 participants randomized to Placebo arm crossed over to open-label pertuzumab.","groupId":"FG001","numSubjects":"50"}],"type":"Crossover From Placebo to Pertuzumab"},{"achievements":[{"groupId":"FG000","numSubjects":"119"},{"groupId":"FG001","numSubjects":"73"}],"comment":"Alive and in Survival Follow-up at End of Study","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"283"},{"groupId":"FG001","numSubjects":"333"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 1196 patients were screened for the study, of whom a total of 808 participants were randomized to one of the two treatment arms."}